Barr Is Latest Generic Firm To Challenge FDA’s Patent-Based Exclusivity Policy

In a D.C. federal court lawsuit, Barr asserts it was the first applicant to file a Paragraph IV certification against any “Orange Book” listed patent for Allegra-D. Consequently, the company says, it should not have to share 180-day generic marketing rights with Impax.